Med Ed Report briefs: March 2014

Share this article:
Carmen Ortiz
Carmen Ortiz

Carmen Ortiz, US Attorney for the District of Massachusetts (pictured), said at the 2014 CBI Pharmaceutical Compliance Congress last month that her office and other government branches have “greater knowledge of the industry” and that more “specialized units and divisions” are being created to investigate and prosecute healthcare fraud, the blog Policy and Medicine reported.

Eli Lilly launched a four-week rotation program for aspiring ­physicians at its Indianapolis headquarters. Students from Tulane University School of Medicine will be the first to participate in the pilot program. The assignments cut across different aspects of the company's business—from drug discovery and development to bioethics and patient safety—and provide third- and fourth-year students “a lens into the industry, its vision and focus on improving patient outcomes,” Lilly said.

According to a post on the New York Times's Hard Cases blog, ­modern medical education may leave newly minted doctors fearful of missing a worst-case diagnosis and therefore too eager to order any expensive tests.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?